Antibiotics and steroids, the double enemies of anticancer immunotherapy: a review of the literature
- 9 November 2020
- journal article
- review article
- Published by Springer Nature in Cancer Immunology, Immunotherapy
- Vol. 70 (6) , 1511-1517
Abstract
The advent of immunotherapy in onco-haematology has represented a kind of revolution that has been able to modify the prognosis of numerous tumours that until recently would have been rapidly lethal. While much is known about the mechanism of action of these drugs, relatively little is known about the factors that represent potential predictors of response and toxicity. Among these factors, the simultaneous administration of antibiotics and/or steroids seems to have a negative impact. Furthermore, several retrospective studies have highlighted the strong link between cancer and gut microbiota, regardless of the tumour site, and how microbiota, playing a key role in the prevention of systemic inflammation at various levels and in the intestinal homeostasis, can be negatively influenced by the dysbiosis caused by antibiotic therapy administered during or in the weeks immediately preceding the start of immunotherapy. Moreover, we assume that the concurrent administration of steroids, which is often necessary in cancer patients, likely results in a deleterious effect on the therapeutic outcomes of immunotherapy. In this review, we will try to clarify the evidence on the possible detrimental effects of antibiotics and steroids, which are currently considered the double enemies of anticancer immunotherapy.Keywords
This publication has 65 references indexed in Scilit:
- Cancer and the Immune System: Basic Concepts and Targets for InterventionSeminars in Oncology, 2015
- PD-L1 Expression as a Predictive Biomarker in Cancer ImmunotherapyMolecular Cancer Therapeutics, 2015
- How Steroids Steer T CellsCell Reports, 2014
- The human microbiome: at the interface of health and diseaseNature Reviews Genetics, 2012
- Macrophage plasticity and polarization: in vivo veritasJournal of Clinical Investigation, 2012
- 9312 Antitumor responses to ipilimumab in advanced melanoma are not affected by systemic corticosteroids used to manage immune-related adverse events (irAEs)European Journal of Cancer Supplements, 2009
- Glucocorticoid amplifies IL‐2‐dependent expansion of functional FoxP3+CD4+CD25+ T regulatory cells in vivo and enhances their capacity to suppress EAEEuropean Journal of Immunology, 2006
- Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: Associations with prednisone, disease‐modifying antirheumatic drugs, and anti–tumor necrosis factor therapyArthritis & Rheumatism, 2006
- Glucocorticoids and Inflammation Revisited: The State of the ArtNeuroimmunomodulation, 2002
- Inhibition of IL-2-induced Jak-STAT signaling by glucocorticoidsProceedings of the National Academy of Sciences, 2000